HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for

First Page		Document Content
Date: 2015-11-10 11:42:30 Chemistry Clinical medicine Organic chemistry MEK inhibitor Protein kinase inhibitors B-Raf inhibitor Sulfonamides Vemurafenib Cobimetinib Keratoacanthoma Ofloxacin		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 719,43 KB Share Document on Facebook

	ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced DocID: 1qm1i - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC. COTELLIC (cobimetinib) tablets, for DocID: 1pQS7 - View Document
	Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra DocID: 1pvTL - View Document
	2016 Technical Achievements in Organic Chemistry Symposium Wednesday August 24, 2016 Terrace Ballroom II - Pennsylvania Convention Center Scott Bagley and Catherine Faler presiding DocID: 1p5wC - View Document
	Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis DocID: 1p0SG - View Document